Cite
Edwards SJ, Nherera L, Trevor N, et al. Cost-Effectiveness of Lithium Versus an Atypical Anti-Psychotic (AAP) used to Augment Treatment with a Selective Serotonin Reuptake Inhibitor (SSRI) in Treatment Resistant Depression (TRD). Value Health. 2014;17(7):A459doi: 10.1016/j.jval.2014.08.1264.
Edwards, S. J., Nherera, L., Trevor, N., & Wakefield, V. (2014). Cost-Effectiveness of Lithium Versus an Atypical Anti-Psychotic (AAP) used to Augment Treatment with a Selective Serotonin Reuptake Inhibitor (SSRI) in Treatment Resistant Depression (TRD). Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A459. https://doi.org/10.1016/j.jval.2014.08.1264
Edwards, S J, et al. "Cost-Effectiveness of Lithium Versus an Atypical Anti-Psychotic (AAP) used to Augment Treatment with a Selective Serotonin Reuptake Inhibitor (SSRI) in Treatment Resistant Depression (TRD)." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A459. doi: https://doi.org/10.1016/j.jval.2014.08.1264
Edwards SJ, Nherera L, Trevor N, Wakefield V. Cost-Effectiveness of Lithium Versus an Atypical Anti-Psychotic (AAP) used to Augment Treatment with a Selective Serotonin Reuptake Inhibitor (SSRI) in Treatment Resistant Depression (TRD). Value Health. 2014 Nov;17(7):A459. doi: 10.1016/j.jval.2014.08.1264. Epub 2014 Oct 26. PMID: 27201281.
Copy
Download .nbib
